Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients

Authors :: Silvia Ferrucci
Simona Tavecchio
L Bonzano
Luigi Macchia
Giulia Calabrese
Maddalena Napolitano
Steven Paul Nisticò
Caterina Foti
Aikaterini Detoraki
Katharina Hansel
Giuseppe Argenziano
Giovanni Pellacani
Paolo Romita
Michela Ortoncelli
Franco Rongioletti
Luca Stingeni
E. Di Leo
Gabriella Fabbrocini
Simone Ribero
M Carbonara
Cataldo Patruno
Eustachio Nettis
Viviana Piras
Danilo Di Bona
Nettis, E
Fabbrocini, G
Ortoncelli, M
Pellacani, G
Argenziano, G
Di Leo, E
Patruno, C
Stingeni, L
Foti, C
Rongioletti, F
Macchia, L
Tavecchio, S
Napolitano, M
Ribero, S
Bonzano, L
Calabrese, G
Di Bona, D
Nisticò, S P
Hansel, K
Romita, P
Piras, V
Carbonara, M
Detoraki, A
Ferrucci, S M
Nettis, E.
Fabbrocini, G.
Ortoncelli, M.
Pellacani, G.
Argenziano, G.
Di Leo, E.
Patruno, C.
Stingeni, L.
Foti, C.
Rongioletti, F.
Macchia, L.
Tavecchio, S.
Napolitano, M.
Ribero, S.
Bonzano, L.
Calabrese, G.
Di Bona, D.
Nistico, S. P.
Hansel, K.
Romita, P.
Piras, V.
Carbonara, M.
Detoraki, A.
Ferrucci, S. M.
Publication Year :: 2021
Abstract: Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for the treatment of moderate-to-severe atopic dermatitis (AD)1 . Our aim was to assess the long-term effectiveness and safety of dupilumab in a clinical real-life setting.

Subjects :: Adult
medicine.medical_specialty
Adult patients
business.industry
Eczema
Interleukin
Dermatology
Atopic dermatitis
medicine.disease
Antibodies, Monoclonal, Humanized
Dupilumab
Dermatitis, Atopic
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Monoclonal
Medicine
Humans
business

Tools